Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 12/20 | 0.35 |
| ▸ | CDK9 | P50750 | 12/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245881 | 0.89 | HTT (0.38) | TERTCHRM1 | |
| SCHEMBL21245650 | 0.85 | SLC5A2 (0.33) | TERTHTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL21245554 | 0.82 | PDE3B (0.42) | TERTGSK3BHTR1AHTR1DHTR1B | |
| SCHEMBL18305056 | 0.81 | TERT (0.34) | CCNT1CDK9TERTHTR1AHTR1D | |
| SCHEMBL4097889 | 0.81 | CHRM1 (0.35) | KCNH2CHRM1 | |
| SCHEMBL29660543 | 0.78 | CDK4 (0.40) | TERTHTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL21245891 | 0.78 | CDK4 (0.40) | TERTHTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL18305041 | 0.76 | NMT1 (0.36) | TERTHTR1AHTR1DHTR1BCHRM1 | |
| SCHEMBL18305072 | 0.76 | SLC5A2 (0.33) | TERTHTR1AHTR1DHTR1BCHRM1 | |
| SCHEMBL20138198 | 0.75 | SLC5A2 (0.35) | TERTCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CCNT1 2299/4885CDK9 1174/4885RORC 1357/4885 |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CCNT1 2019/4885CDK9 1211/4885RORC 1473/4885 |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | CCNT1 40/4885CDK9 3/4885RORC 772/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CCNT1 37/4885CDK9 7/4885RORC 1073/4885 |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CCNT1 2299/4885CDK9 1174/4885RORC 1357/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CCNT1 37/4885CDK9 7/4885RORC 1073/4885 |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CCNT1 2019/4885CDK9 1211/4885RORC 1473/4885 |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CCNT1 2319/4885CDK9 1140/4885RORC 1347/4885 |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CCNT1 2319/4885CDK9 1140/4885RORC 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.